0000000000280269

AUTHOR

Marion Muche

showing 4 related works from this author

PNPLA3 and HSD17B13 gene variants exert opposite effects on fatty liver phenotypes: results from the FLAG cohort

2020

GeneticsFatty liverCohortmedicineBiologymedicine.diseasePhenotypeGeneFlag (geometry)Zeitschrift für Gastroenterologie
researchProduct

Baseline patient characteristics of the German multicentric prospective real-world NAFLD cohort: The Fatty Liver Assessment in Germany (FLAG) study

2019

medicine.medical_specialtybusiness.industryFatty liverPatient characteristicsmedicine.diseaselanguage.human_languageGermanInternal medicineCohortlanguagemedicineFLAG (chemotherapy)Baseline (configuration management)business35. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber
researchProduct

Effects of the common PNPLA3 p.I148 M polymorphism on the fatty liver phenotypes in German patients: results from the FLAG “real life” cohort

2019

GermanGeneticsFatty liverCohortlanguagemedicineBiologymedicine.diseasePhenotypelanguage.human_languageZeitschrift für Gastroenterologie
researchProduct

The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care

2020

Background & Aims NAFLD is a growing health concern. The aim of the Fatty Liver Assessment in Germany (FLAG) study was to assess disease burden and provide data on the standard of care from secondary care. Methods The FLAG study is an observational real-world study in patients with NAFLD enrolled at 13 centres across Germany. Severity of disease was assessed by non-invasive surrogate scores and data recorded at baseline and 12 months. Results In this study, 507 patients (mean age 53 years; 47% women) were enrolled. According to fibrosis-4 index, 64%, 26%, and 10% of the patients had no significant fibrosis, indeterminate stage, and advanced fibrosis, respectively. Patients with advanced fib…

NAFLD non-alcoholic fatty liver diseasemedicine.medical_specialtyBMI body mass indexNASH non-alcoholic steatohepatitisLiver fibrosisLSM liver stiffness measurementAST aspartate aminotransferaseLiver diseaseFLAG Fatty Liver Assessment in GermanyNAFLDALT alanine aminotransferaseInternal medicineAPRI aspartate-aminotransferase-to-platelet ratio indexInternal MedicineNAFL non-alcoholic fatty liverImmunology and AllergyMedicineddc:610Co-morbiditieslcsh:RC799-869FIB-4 fibrosis-4Disease burdenHepatologyFAST FibroScan-ASTGGT gamma-glutamyltransferasebusiness.industryFatty liverNASHGastroenterologyReal worldGLP-1 glucagon-like peptide-1T2DM type 2 diabetes mellitusCVE cardiovascular eventmedicine.diseaseMetabolic syndromeCohortlcsh:Diseases of the digestive system. GastroenterologyCAP controlled attenuation parameterSteatohepatitisMetabolic syndromebusinessBody mass indexResearch ArticleCohort studyJHEP Reports
researchProduct